FHD-909 is an oral, first-in-class allosteric small molecule selectively inhibiting SMARCA2 (BRM) ATPase over SMARCA4 (BRG1), both central catalytic subunits of BAF chromatin-remodeling complexes.
In today's Pharmaceutical Executive Daily, Foghorn Therapeutics and Eli Lilly discontinue development of FHD-909, their oral ...
Novartis secured an exclusive worldwide license to Abogen’s Abo2203 and options on additional RNA-platform programs, positioning mRNA-encoded biologic expression as a scalable autoimmune therapeutic ...
CORXEL’s Dr. Bo Liang on why small molecule oral therapies will be the long-term winners in a GLP-1 market driven by consumer preference. The GLP-1 landscape is a fast-evolving sector of the industry.
Dr. Liang previously worked at Novo Nordisk, where he lead global clinical development and regulatory submission for ...
FDA Approves Expanded Indication for Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy
FDA broadened Camzyos use to symptomatic oHCM in adults and pediatric patients ≥30 kg, representing the first adolescent ...
MRD testing is transforming oncology trials — compressing timelines, enriching populations, and generating earlier answers.
Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael Abrams questions ...
Four long-acting antibodies will be jointly advanced, targeting IL-13, IL-4, IL-4Rα, and IL-4xIL-13, extending type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results